Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Alice Tzeng, Byron H. Kwan, Cary F. Opel, et al.
Proceedings of the National Academy of Sciences (2015) Vol. 112, Iss. 11, pp. 3320-3325
Open Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Kelly D. Moynihan, Cary F. Opel, Gregory L. Szeto, et al.
Nature Medicine (2016) Vol. 22, Iss. 12, pp. 1402-1410
Open Access | Times Cited: 485
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel‐Adriano Silva, Shawn Yu, Umut Y. Ulge, et al.
Nature (2019) Vol. 565, Iss. 7738, pp. 186-191
Open Access | Times Cited: 456
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Weilei Hu, Guosheng Wang, Dongsheng Huang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 360
Delivering safer immunotherapies for cancer
Lauren E. Milling, Yuan Zhang, Darrell J. Irvine
Advanced Drug Delivery Reviews (2017) Vol. 114, pp. 79-101
Open Access | Times Cited: 273
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein, Inja Waldhauer, Valeria Nicolini, et al.
OncoImmunology (2017) Vol. 6, Iss. 3, pp. e1277306-e1277306
Open Access | Times Cited: 241
Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
Yuan Zhang, Na Li, Heikyung Suh, et al.
Nature Communications (2017) Vol. 9, Iss. 1
Open Access | Times Cited: 220
Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy
Noor Momin, Naveen K. Mehta, Nitasha R. Bennett, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 498
Open Access | Times Cited: 177
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Zhichen Sun, Zhenhua Ren, Kaiting Yang, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 173
Interleukin-1 as Innate Mediator of T Cell Immunity
Bram Van Den Eeckhout, Jan Tavernier, Sarah Gerlo
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 142
Engineering cytokine therapeutics
Jeroen Deckers, Tom Anbergen, Ayla M. Hokke, et al.
Nature Reviews Bioengineering (2023) Vol. 1, Iss. 4, pp. 286-303
Open Access | Times Cited: 119
Engineering interferons and interleukins for cancer immunotherapy
Patrick G. Holder, Shion A. Lim, Christine Huang, et al.
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114112-114112
Open Access | Times Cited: 95
Targeted modulation of immune cells and tissues using engineered biomaterials
Parisa Yousefpour, Kaiyuan Ni, Darrell J. Irvine
Nature Reviews Bioengineering (2023) Vol. 1, Iss. 2, pp. 107-124
Open Access | Times Cited: 83
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
Diyuan Xue, Benjamin Moon, Jing Liao, et al.
Science Immunology (2022) Vol. 7, Iss. 67
Open Access | Times Cited: 80
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer
Bing Feng, Zhiliang Bai, Xiaolei Zhou, et al.
Nature (2024) Vol. 634, Iss. 8034, pp. 712-720
Open Access | Times Cited: 23
Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
Giulio Casi, Dario Neri
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 22, pp. 8751-8761
Closed Access | Times Cited: 160
Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Dario Neri
Cancer Immunology Research (2019) Vol. 7, Iss. 3, pp. 348-354
Open Access | Times Cited: 127
IL-2 and Beyond in Cancer Immunotherapy
John Wrangle, Alicia Patterson, Christopher Johnson, et al.
Journal of Interferon & Cytokine Research (2018) Vol. 38, Iss. 2, pp. 45-68
Open Access | Times Cited: 109
Targets and Antibody Formats for Immunotherapy of Neuroblastoma
Jeong A Park, Nai‐Kong V. Cheung
Journal of Clinical Oncology (2020) Vol. 38, Iss. 16, pp. 1836-1848
Open Access | Times Cited: 106
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
Cornelia Hutmacher, Dario Neri
Advanced Drug Delivery Reviews (2018) Vol. 141, pp. 67-91
Closed Access | Times Cited: 91
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
Inja Waldhauer, Valeria Gonzalez‐Nicolini, Anne Freimoser–Grundschober, et al.
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 91
Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Ivan S. Pires, Paula T. Hammond, Darrell J. Irvine
Advanced Therapeutics (2021) Vol. 4, Iss. 8
Open Access | Times Cited: 73
Next-generation cytokines for cancer immunotherapy
Diyuan Xue, Eric J. Hsu, Yang‐Xin Fu, et al.
Antibody Therapeutics (2021) Vol. 4, Iss. 2, pp. 123-133
Open Access | Times Cited: 61
Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
Jingya Guo, Yong Liang, Diyuan Xue, et al.
Cell Research (2021) Vol. 31, Iss. 11, pp. 1190-1198
Open Access | Times Cited: 61
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
Alfredo Quijano‐Rubio, M. Aladdin Bhuiyan, Huilin Yang, et al.
Nature Biotechnology (2022) Vol. 41, Iss. 4, pp. 532-540
Open Access | Times Cited: 51
Biomaterials-Mediated Engineering of the Immune System
Coralie M. Backlund, Sasan Jalili‐Firoozinezhad, Byungji Kim, et al.
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 153-179
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top